Karenitecin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer

This study has been completed.

Study NCT00010218 Information provided by Cancer and Leukemia Group B

First Received: February 2, 2001 Last Updated: March 22, 2011 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	January 2006
Primary Completion Date:	April 2003 (Final data collection date for primary outcome measure)

Publications:

Miller AA, Herndon JE 2nd, Gu L, Green MR; Cancer and Leukemia Group B. Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004). Lung Cancer. 2005 Jun;48(3):399-407. Epub 2005 Jan 23.

Herndon JE, Miller AA, Zhang C, et al.: Phase II trial of karenitecin in patients with refractory non-small cell lung cancer (NSCLC): CALGB 30004 . [Abstract] Proceedings of the American Society of Clinical Oncology 22: A-2706, 673, 2003.